NCT03023046View on ClinicalTrials.gov

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 23, 2017

Primary Completion Date

May 20, 2021

Study Completion Date

May 1, 2022

Conditions
Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Dasatinib

Given PO

DRUG

Doxorubicin

Given IV

DRUG

Etoposide

Given IV

DRUG

Imatinib Mesylate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT03023046 - Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Biotech Hunter | Biotech Hunter